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Polygenic Risk for Schizophrenia Is Associated with
Cognitive Change Between Childhood and Old Age
Andrew M. McIntosh, Alan Gow, Michelle Luciano, Gail Davies, David C. Liewald,
Sarah E. Harris, Janie Corley, Jeremy Hall, John M. Starr, David J. Porteous, Albert Tenesa,
Peter M. Visscher, and Ian J. Deary
Background: Genome-wide association studies (GWAS) have shown a polygenic component to the risk of schizophrenia. The disorder
is associated with impairments in general cognitive ability that also have a substantial genetic contribution. No study has determined
whether cognitive impairments can be attributed to schizophrenia’s polygenic architecture using data from GWAS.
Methods: Members of the Lothian Birth Cohort 1936 (LBC1936, n ¼ 937) were assessed using the Moray House Test at age 11 and with
the Moray House Test and a further cognitive battery at age 70. To create polygenic risk scores for schizophrenia, we obtained data
from the latest GWAS of the Psychiatric GWAS Consortium on Schizophrenia. Schizophrenia polygenic risk profile scores were calculated
using information from the Psychiatric GWAS Consortium on Schizophrenia GWAS.
Results: In LBC1936, polygenic risk for schizophrenia was negatively associated with IQ at age 70 but not at age 11. Greater polygenic
risk for schizophrenia was associated with more relative decline in IQ between these ages. These findings were maintained when the
results of LBC1936 were combined with that of the independent Lothian Birth Cohort 1921 (n ¼ 517) in a meta-analysis.
Conclusions: Increased polygenic risk of schizophrenia is associated with lower cognitive ability at age 70 and greater relative decline
in general cognitive ability between the ages of 11 and 70. Common genetic variants may underlie both cognitive aging and risk of
schizophrenia.
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S
chizophrenia is a familial disorder in which genetic factors
account for approximately 80% of the total variation in
liability (1). Schizophrenia is frequently associated with
lifelong disability and with impaired cognitive test performance
that is not effectively treated with current antipsychotic treat-
ments (2). Reduced general cognitive ability has also been found
in children who later develop schizophrenia (3–5), in people at
high genetic risk of psychosis (6,7), and studies of unaffected
adult relatives (8). Bivariate genetic studies (in affected patients
and their families) suggest that the phenotypic correlation
between cognitive ability and risk of schizophrenia is substantial
and up to 92% of their covariance is due to common genetic
factors (9,10). These shared genetic causes have not yet been
attributed to sets of specific single nucleotide polymorphisms
(SNPs). Whether these genetic risk factors confer a long-term,
stable deficit in cognitive ability, a greater risk of cognitive
decline over time, or both is also not known.
General cognitive ability is substantially stable over time, with
a correlation of .6 between measures of IQ taken at ages 11
and 70 (11). General cognitive ability also has a strong genetic
basis (12,13). By adolescence and throughout adulthood, well
over 50% of its variation is due to genetic factors (12). Using
genome-wide SNP data, we have estimated that common
variants account for 24% of the change in general cognitive
ability from age 11 to age 70. These findings warrant a search for
genetic variants that influence both the enduring stable trait of
cognitive ability and its change across the life course after
childhood.
In the present study, we tested the hypothesis that having
more of the common, risk-associated genetic variants for schizo-
phrenia is associated with lower cognitive ability in childhood
and old age and relatively more decline in between. While a
relationship between genetic risk of schizophrenia and cognition
has been based largely on studies of affected individuals, we
sought to address this issue in a sample of individuals from the
healthy population. We studied the Lothian Birth Cohort 1936
(LBC1936) (14) whose participants have cognitive function data in
childhood and old age and genome-wide SNP data. We used
information from the latest available genome-wide association
study (GWAS) of the Psychiatric GWAS Consortium on Schizo-
phrenia (PGC-SCZ) release to provide individual polygenic risk
profile scores (15).
Methods and Materials
Subjects
The Lothian Birth Cohort 1936 comprises 1091 community-
dwelling individuals without dementia (548 men and 543
women), residing in or around the city of Edinburgh, Scotland
(14,16). Most of the LBC1936 had participated in the Scottish
Mental Survey 1947 at a mean age of 10.9 years and then in a
follow-up assessment approximately 59 years later at a mean age
of 69.5 years (SD .8). These assessments are referred to as ages 11
and 70 throughout. All subjects were asked questions about their
medical history.
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Cognitive Testing
Most LBC1936 participants undertook the Moray House Test
(MHT) at age 11 (14). They retook the MHT at about age 70. The
MHT is a group-administered, paper-and-pencil test that has a time
limit of 45 minutes and has a preponderance of verbal reasoning
items with some arithmetical and abstract items. Moray House
Test scores were converted into an IQ-type scale, with a mean
of 100 and SD ¼ 15, as we have done elsewhere (17). At age 70,
participants completed an additional cognitive test battery of
psychometric tests from the Wechsler Adult Intelligence Scale-
Third Edition (18) and Wechsler Memory Scale-Third Edition (19),
including digit symbol coding, block design, matrix reasoning,
digit span backwards, symbol search, and letter-number sequen-
cing. The additional tasks resulted in a measure of cognitive ability
at age 70 that had a greater number of fluid-type tasks. Principal
component analysis derived scores were then computed for
general cognitive ability, memory, and processing speed (20).
Genotyping and Risk Profile Score Calculation
Details of the GWAS sample collection, processing, and quality
control have been described elsewhere (12). Genomic DNA
was extracted from venous blood of members of LBC1936. Geno-
typing was conducted at the Wellcome Trust Clinical Research
Facility, Edinburgh, United Kingdom (www.wtcrf.ed.ac.uk) and
used the Illumina 610-Quadv1 whole-genome SNP array (San
Diego, California). Single nucleotide polymorphisms were exclu-
ded from the polygenic analysis where the minor allele frequency
was less than 2%, if the call rate was less than 98%, or if the
chi-squared test for Hardy–Weinberg equilibrium was less than
.001. Strand ambiguous SNPs were also removed. The resulting
SNP set was then used to calculate four multidimensional scaling
(MDS) components to assess for population stratification and
adjust for this in later analyses. The data were then imputed to
HapMap version 3 using MACH software (Centre for Statistical
Genetics, University of Michigan; http://www.sph.umich.edu/csg/
abecasis/MACH) and then converted back to PLINK (MAP/PED;
http://pngu.mgh.harvard.edu/purcell/plink/) format for later analysis.
Summary results from the most recent international GWAS of
9394 individuals with schizophrenia (21) and 12,462 control
subjects were obtained from PGC-SCZ. Details of the methods
used by the consortium are given elsewhere (21). Polygenic
profile scores were calculated according to the methods
described by Purcell et al. (15). Four lists of significant SNPs were
generated from the PGC-SCZ association data, at significance
thresholds of p  .5, p  .1, p  .05, and p  .01. These were
used to select SNPs with a minor allele frequency of at least 2%
from our LBC1936 GWAS data set, resulting in four separate files
that contained the genotypes of each individual. To identify
polygenic effects due to independent SNPs in linkage equilibrium
with one another, each SNP set was then pruned using the
variance inflation factor that is equivalent to 1/(1R2) (where R is
the multiple regression coefficient for a SNP being regressed on
all other SNPs simultaneously). Linkage equilibrium-based SNP
pruning was conducted in a sliding window of 50 SNPs, with
each calculation performed iteratively by moving the window by
five SNPs. Single nucleotide polymorphisms were conservatively
selected on the basis of a variance inflation factor of 2 or less.
Finally, to obtain polygenic risk profile scores for schizophrenia,
these four SNP sets were then scored using the sum of the
number of reference alleles multiplied by the logarithm of odds
ratio for schizophrenia across the whole genome.
All analyses were performed in PLINK with the exception of
imputation to HapMap version 3 and data manipulation, which were
performed in MACH (www.sph.umich.edu/csg/abecasis/MACH) and
R software (R Project for Statistical Computing; www.r-project.org),
respectively.
Statistical Analyses
All statistical analyses were conducted in the R statistical
software package (http://www.r-project.org/) using linear regression
models that were adjusted for the first four MDS components
measuring population stratification for gender and for a previous
history of diabetes, stroke, or hypertension, as these conditions have
previously been shown to adversely affect cognition or cognitive
aging (22–24). We examined the association between polygenic risk
profile scores for schizophrenia at all four thresholds and cognitive
ability in childhood IQ from the MHT at age 11 and cognitive ability
in old age (IQ from the MHT at age 70 and then from six tests at age
70). In total, 937 people provided data for analysis.
We examined the relationship between polygenic risk profile
scores for schizophrenia and participants’ relative cognitive
change between childhood and old age. This long-term cognitive
change was derived as follows. The relationship between IQ at
ages 11 and 70 could be summarized using a linear regression
model in which the residual value reflected the observed
deviation in IQ at age 70 based on that predicted by IQ at age
11. They represent an estimate of cognitive change for each
LBC1936 participant with the relevant data. Negative values
reflect a decline in function relative to that of others in the
sample. Change scores were also estimated for general cognitive
ability after adjustment for age 11 IQ.
Replication Sample
Significant relationships between polygenic risk for schizo-
phrenia and cognitive ability or cognitive ability change were
then examined in the smaller Lothian Birth Cohort of 1921
(LBC1921) (25). The LBC1921 sample contributed 517 individuals
to the current analysis who participated in the Scottish Mental
Survey of 1932 when they were aged 11 years. The MHT number
12 was administered at age 11 and again at age 79, when Raven
et al. (26) standard progressive matrices, verbal fluency (27), and
logical memory (28) tests were also administered. General
cognitive ability was measured using the MHT alone and from
the first principal component of the four cognitive tests at age
79. Processing methods and the subsequent analyses, including
GWAS, were nearly identical to the methods used in LBC1936.
The analyses were all adjusted for gender, the first four GWAS-
MDS components, and for the presence of a previous diagnosis
of diabetes, hypertension, or vascular disease.
In addition for testing for replication of significant findings
across the two cohorts LBC1936 and LBC1921, we also conducted
a meta-analysis of the results from the two studies. A fixed-effects
model was used in which the standardized regression coefficients
were weighted by the inverse of their squared standard error and
pooled to provide a summary estimate across both cohorts.
Results
A total sample of 937 (479 women and 458 men) individuals
contributed both genome-wide and cognitive data to the
analysis of the LBC1936, none of whom were known to suffer
from schizophrenia. Three hundred sixty-nine people (39%) had a
history of hypertension, 82 (9%) had a history of diabetes, and
46 (5%) had a history of previous stroke. We adjusted for these
variables in all subsequent analyses.
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Relationship of Polygenic Score to Cognition
Polygenic risk for schizophrenia (derived separately using four
significance thresholds) was not associated with IQ at age 11 (Table
S1 in Supplement 1). Polygenic risk for schizophrenia showed a
weak, nonsignificant association with MHT-derived IQ at age 70 at
p thresholds of .5 (Table 1: beta ¼ .06, p ¼ .09) and .1 (Table 1:
beta ¼ .06, p ¼ .08). Polygenic risk for schizophrenia was
significantly associated with general cognitive ability at age 70,
as based on the six nonverbal subtests from the Wechsler battery,
at all four GWAS thresholds (range of p values .005 to .02; Table 1).
Relationship of Polygenic Score to Change in Cognition
Greater polygenic risk for schizophrenia was associated with
relatively greater decline in IQ from age 11 to age 70 (based on
MHT scores adjusted for IQ at age 11) at the GWAS threshold of
p ¼ .01 (beta ¼ .07, p ¼ .03). A trend was observed for the
threshold of p ¼ .1 (Table 2: beta ¼ .07, p ¼ .05). When lifetime
cognitive change was derived from the six Wechsler nonverbal
tests at age 70 adjusted for IQ at age 11, polygenic risk for
schizophrenia was associated with lower than expected general
cognitive ability at all four GWAS significance thresholds (range
of p values .004 to .008; Table 2). Judged by the change in the
model R2 statistic, the proportion of variance in cognitive ability
change between ages 11 and 70 (using the Wechsler tests)
explained by polygenic risk for schizophrenia was between .8% at
a GWAS threshold of p ¼ .5 to .9% at the threshold of p ¼ .005.
Replication in LBC1921
Three out of four of the significant associations between
polygenic risk for schizophrenia and general cognitive ability at
age 70 in LBC1936 were in the same direction in the smaller
LBC1921 cohort at age 79. Polygenic risk for schizophrenia at the
GWAS threshold of p ¼ .01 additionally showed a significant
negative association with general cognitive ability at age 79
(Table 3: standardized beta ¼ .11, p ¼ .03) in LBC1921. This
finding replicated the association found in LBC1936 in both
direction and significance.
The significant negative association between polygenic risk of
schizophrenia at a threshold of p ¼ .01 and relative change in
cognitive ability measured using the MHT in LBC1936 was also in
the same direction in LBC1921 (standardized beta ¼ .04, p ¼ .38).
When IQ was determined using four tests in LBC1921, the negative
associations between polygenic risk of schizophrenia and change in
cognitive ability remained in the same direction for all but the
GWAS threshold of p ¼ .5 (Table 3). None of these findings were
individually significant in LBC1921 (which has a much smaller
sample size).
Fixed-effects meta-analysis using data from both cohorts
showed a significant negative association between polygenic
risk for schizophrenia and general cognitive ability in the eighth
decade using the composite measure derived from four or six
separate tests (significant negative association with general
cognitive ability at GWAS thresholds .1, .05, and .01; Table 3).
Polygenic risk for schizophrenia was also significantly and
negatively associated with change in cognitive ability from ages
11 to 70 or 79 using the MHT (GWAS threshold p ¼ .01:
standardized beta ¼ .06, p ¼ .036). This negative association
was also found using the estimate of change in cognitive ability
based upon the four or six tests at GWAS thresholds of .1, .05,
and .01 (Table 3).
Discussion
Greater polygenic risk for schizophrenia is associated with
lower fluid-type general cognitive ability at age 70 but not at
age 11. Furthermore, greater polygenic risk for schizophrenia is
associated with a greater relative decline in general cognitive
functioning between age 11 and age 70. These results were
significant when the verbal reasoning dominated Moray House
Test was used and when using a more extensive cognitive
battery that incorporated nonverbal, fluid intelligence type tests
from the Wechsler battery.
The association of polygenic risk for schizophrenia with
cognitive ability at age 70 independently replicated partially in
LBC1921 at age 79, at the GWAS threshold of p ¼ .01. The
direction of each statistically significant effect in LBC1936 was
broadly replicated in LBC1921 for all but the most liberal of the
GWAS thresholds (p ¼ .5). Meta-analysis of the findings from both
LBC1921 and LBC1936 also supported a significant negative
Table 1. Polygene Scores and Cognitive Ability at Age 70 in 937 People from LBC1936
Threshold Cognitive Ability at Age 70 from MHT Cognitive Ability at Age 70 from Six Wechsler Tests
p ¼ .5 Beta ¼ .06, t ¼ 1.68, p ¼ .09, R2 ¼ .3 Beta ¼ .10, t ¼ 2.80, p ¼ .005, R2 ¼ .8
p ¼ .1 Beta ¼ .06, t ¼ 1.74, p ¼ .08, R2 ¼ .3 Beta ¼ .09, t ¼ 2.46, p ¼ .01, R2 ¼ .6
p ¼ .05 Beta ¼ .03, t ¼ .97, p ¼ .33, R2 ¼ .1 Beta ¼ .08, t ¼ 2.45, p ¼ .01, R2 ¼ .6
p ¼ .01 Beta ¼ .05, t ¼ 1.40, p ¼ .16, R2 ¼ .2 Beta ¼ .08, t ¼ 2.30, p ¼ .02, R2 ¼ .6
Beta, standardized regression coefficient representing change in dependent variable for unit change in polygene profile scores, where both are
measured in standard deviation units; LBC1936, Lothian Birth Cohort 1936; MHT, Moray House Test; R2, estimate of variance in cognitive ability explained
by polygene score in %.
Table 2. Polygenic Scores and Cognitive Ability Change Between Age 11 and Age 70 in 937 People from LBC1936
Threshold
Change in Cognitive Ability from
Age 11 to Age 70 from MHT
Change in Cognitive Ability from Age 11
to Age 70 from Six Wechsler Tests
p ¼ .5 Beta ¼ .04, t ¼ 1.12, p ¼ .26, R2 ¼ .1 Beta ¼ .08, t ¼ 2.44, p ¼ .015, R2 ¼ .6
p ¼ .1 Beta ¼ .07, t ¼ 1.93, p ¼ .05, R2 ¼ .4 Beta ¼ .09, t ¼ 2.68, p ¼ .007, R2 ¼ .8
p ¼ .05 Beta ¼ .04, t ¼ 1.19, p ¼ .23, R2 ¼ .2 Beta ¼ .10, t ¼ 2.89, p ¼ .004, R2 ¼ .9
p ¼ .01 Beta ¼ .07, t ¼ 2.14, p ¼ .03, R2 ¼ .5 Beta ¼ .10, t ¼ 2.93, p ¼ .003, R2 ¼ .9
Beta, standardized regression coefficient; LBC1936, Lothian Birth Cohort 1936; MHT, Moray House Test; R2, estimate of
variance in cognitive ability explained by polygene score in %.
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association between polygenic risk for schizophrenia and both
general cognitive ability in old age and cognitive ability change
from childhood to old age.
Cognition is impaired in schizophrenia (29) and more recent
studies have demonstrated that cognitive deficits may be seen
premorbidly and in the unaffected close relatives of people with
schizophrenia (5,8). We are not aware of any studies that have
serially measured cognition over time in a population-based
cohort and then related these measurements to polygenic risk of
schizophrenia. These cognitive changes occurred between age 11
and the eighth decade of life, and the precise timing and
trajectory of these changes could not be determined in the
current study. Therefore, while these changes are likely to be
related to brain plasticity, it is not possible to identify whether
the changes were related specifically to neurodevelopmental
factors. Because the LBC1936 is a year-of-birth sample of mainly
healthy people living in the community, these findings suggest
that common genetic risk variants for schizophrenia may accel-
erate cognitive aging independent of the clinical illness.
Studies of specific genetic risk factors, such as those identified
in DISC1 or NRG1, as well as some genome-wide significant
variants, have demonstrated an association between the risk
allele and cognitive impairment in one or more domains (30–32).
It is likely, however, that these variants individually capture less
than 1% of the total risk to schizophrenia and cumulatively less
than 5% of the total risk to the disorder (21). A significant
proportion of the missing heritability to schizophrenia may lie in
the variants that do not survive multiple testing corrections
across the whole genome in GWAS studies. Recently, Lee et al.
(33) have shown that up to 25% of the risk for schizophrenia can
be attributed to variants that do not reach whole-genome
significance. This implies that a polygenic approach to estimating
individualized risk, taking in SNPs with p values  .5, may be able
to provide better phenotype predictions. This may be especially
true in adult samples where general cognitive ability may be
more strongly influenced by genetic factors than in children (34).
The current findings suggest that common risk variants for
schizophrenia are in combination associated with greater decline
in general cognitive ability between age 11 and age 70. This
builds upon a large body of literature showing a decline in
general cognitive function over time in people at high genetic
risk who later develop schizophrenia (3,7) and upon studies that
show a reduction over time in cognitive function in well relatives
and affected patients. The proportion of genetic variance for
schizophrenia shared with that for premorbid intelligence is
modest (35) and less than initially expected (9). Fowler et al.
(35) suggested that the phenotypic correlation between intelli-
gence and schizophrenia might be caused by the onset of
psychosis. However, that study was not in a position to test
the phenotypic correlation between psychosis and age-related
cognitive change or the proportion of genetic variance that they
share. The present study points to cognitive change and not prior
cognition as the companion of schizophrenia risk.
Identifying traits that are genetically correlated with schizo-
phrenia may also have statistical advantages for the identification
of new quantitative trait loci (36). It is also possible, as GWAS
samples increase and more of the heritability is captured by
genotyping, that polygenic profiling will capture a greater
proportion of variance in risk of schizophrenia. Assuming a
constant genetic correlation with cognitive ability, the proportion
of variance in cognition and cognitive aging explained by
polygenetic risk of schizophrenia can also be expected to
increase. This has important implications for the eventual clinical
usefulness of polygenetic profiling in schizophrenia, although
future studies will also need to address the diagnostic specificity
of these findings.
The present study has some potential limitations. First, the
cognitive test applied at age 11 (the Moray House Test) is not
one that is in common use today and contemporary tests of
cognition may have provided more accurate estimates of
cognitive ability. However, previous studies have demonstrated
a very high correlation (.8 or more) between the MHT scores and
individually administered cognitive assessments in childhood
(Binet tests) (37) and old age (Wechsler tests) (38), suggesting
that its use as a measure of general intelligence has concurrent
validity across the life course (39). Second, some of the results
reported here would not survive stringent multiple testing
corrections. However, the study’s principal hypothesis concerned
an association between polygenic risk profile scores and a decline
in general cognitive ability and was supported using data from
Table 3. Polygenic Scores and Cognitive Ability in 517 People from LBC1921 and LBC1921 and LBC1936 Combined (n ¼ 1434)
Threshold Cognitive Ability at Age 79 from Four Tests in LBC1921
Meta-Analysis of LBC1921 and LBC1936
Fixed Effects Estimate
p ¼ .5 Beta ¼ .045, SE ¼ .050, t ¼ .91, p ¼ .36 Beta ¼ .05, z ¼ 1.92, p ¼ .054
p ¼ .1 Beta ¼ .083, SE ¼ .0497, t ¼ 1.66, p ¼ .097 Beta ¼ .08, z ¼ 3.43, p ¼ .0006
p ¼ .05 Beta ¼ .065, SE ¼ .050, t ¼ 1.30, p ¼ .20 Beta ¼ .08, z ¼ 2.68, p ¼ .007
p ¼ .01 Beta ¼ .11, SE ¼ .0519, t ¼ 2.17, p ¼ .03 Beta ¼ .09, z ¼ 3.08, p ¼ .002
Change in Cognitive Ability from Age 11 to Age 79
from MHT in LBC1921
Meta-Analysis of LBC1921 and LBC1936
Fixed Effects Estimate
p ¼ .01 Beta ¼ .04, SE ¼ .050, t ¼ .89, p ¼ .38 Beta ¼ .06, z ¼ 2.10, p ¼ .036
Change in Cognitive Ability from Age 11 to Age 79
from Four Tests in LBC1921
Meta-Analysis of LBC1921 and LBC1936
Fixed Effects Estimate
p ¼ .5 Beta ¼ .05, SE ¼ .049, t ¼ .99, p ¼ .32 Beta ¼ .04, z ¼ 1.42, p ¼ .15
p ¼ .1 Beta ¼ .03, SE ¼ .049, t ¼ .65, p ¼ .52 Beta ¼ .07, z ¼ 2.52, p ¼ .01
p ¼ .05 Beta ¼ .02, SE ¼ .050, t ¼ .40, p ¼ .69 Beta ¼ .07, z ¼ 2.66, p ¼ .008
p ¼ .01 Beta ¼ .06, SE ¼ .052, t ¼ 1.24, p ¼ .21 Beta ¼ .09, z ¼ 3.01, p ¼ .003
Beta, standardized regression coefficient; LBC1921, Lothian Birth Cohort 1921; LBC1936, Lothian Birth Cohort 1936; MHT, Moray House Test; SE,
standard error.
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both the MHT and a general cognitive factor derived from six
nonverbal Wechsler subtests. The finding of greater cognitive
aging using the general cognitive battery would have survived
false discovery rate correction (40) at all four GWAS p value
thresholds. Third, it should be noted that the effects sizes
reported in the current study are small and do not imply that
the overlap in genetic architecture between cognitive ability,
cognitive aging, and schizophrenia is substantial.
The failure to replicate the significant association in LBC1936
between polygenic risk for schizophrenia and change in cognitive
ability in LBC1921 may also be seen as a limitation. The
substantially smaller sample size in LBC1921 compared with
LBC1936, as well as their more advanced years and greater
comorbidity, may explain this apparent discrepancy. Neverthe-
less, the meta-analysis of findings from both studies supports our
overall findings and conclusions.
The current study finds that polygenic risk for schizophrenia
determined from GWAS contributes significantly to variation in
the age-related decline of general cognitive ability in a commu-
nity dwelling sample assessed at age 11 and age 70. These
findings were made in predominantly healthy, community-
dwelling individuals and were therefore not simply due to the
effects of chronic psychosis or its treatment. Cognitive aging is
growing in importance as a personal, social, and economic
burden on societies (41). It appears to be partly heritable (11);
yet, the specific genes are elusive (42). This new clue to the
location of some of the genetic variation in cognitive aging could
aid the mechanistic understanding of both cognitive aging and
schizophrenia and the link between them.
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